|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 瑞格列克>> 市场分析报告 |
瑞格列克市场分析报告 |
|
RELUGOLIX (TAK-385) - Emerging Insight and Market Forecast – 2030 ... the growth of prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and ... for women with endometriosis. Relugolix monotherapy tablet (120 mg) is under ... and access to available databases. RELUGOLIX (TAK-385) Analytical Perspective ... Global Relugolix API Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029 ... a total of 15 chapters: Chapter 1, to describe Relugolix API product scope, market overview ... to profile the top manufacturers of Relugolix API, with price, sales, revenue ... industry chain of Relugolix API. Chapter 14 and 15, to describe Relugolix API sales ... Global Relugolix API Supply, Demand and Key Producers, 2023-2029 ... well as details the characteristics of Relugolix API that contribute to its ... manufacturers and share Global Relugolix API production by manufacturer, production ... Type Purity ? 98 % Purity ? 99 % Global Relugolix API Market, Segmentation by Application ... Global Relugolix API Market Growth 2025-2031 ... analysis in US$ millions of the world Relugolix API industry. This Insight Report ... leading global companies with a focus on Relugolix API portfolios and capabilities, market ... market shares, and growth opportunities of Relugolix API market by product type, ... Global Relugolix API Market Research Report 2024(Status and Outlook) ... focused on expanding the applications of Relugolix API are expected to drive ... of targeted therapies that incorporate Relugolix API. This trend is driven by ... is emerging as a lucrative market for Relugolix API, driven by growing investments in healthcare ... Prostate Cancer – Pipeline Insight, 2020 ... Prostate Cancer Emerging Drugs Relugolix: Myovant Relugolix is the Myovant’s lead product ... , with potential antineoplastic activity. Relugolix competitively binds to and blocks ... prostate cancer cell proliferation. Relugolix is similar to the approved GnRH ... Endometriosis - Pipeline Insight, 2021 ... trials in Japan. Relugolix: Myovant Sciences Relugolix Combination Tablet consists of relugolix 40 mg, estradiol ... 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination ... Canada Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pain Medication, Hormonal Suppression Therapy), By Drug Class, By Route Of Administration, By Distribution Channel, By State, And Segment Forecasts, 2025 - 2033 The Canada endometriosis treatment market size was estimated at USD 53.58 million in 2024 and is projected to reach USD 156.71 million by 2033, growing at a CAGR of 13.26% from 2025 to 2033. The growth is driven by increasing awareness, advancements in ... Global Estradiol-Norethindrone Acetate Tablets Market Growth 2024-2030 ... various symptoms caused by menopause, while Relugolix-estradiol-norethindrone acetate tablets are ... . Segmentation by Type: Estradiol-Norethindrone Acetate Relugolix-Estradiol-Norethindrone Acetate Segmentation by Application ... Global Uterine Fibroid Treatment Drugs Market Size study & Forecast, By Drug Class (Gonadotropin-releasing Hormone (GnRH) Agonists, Gonadotropin-releasing Hormone (GnRH) Antagonists, Progestin-releasing Intrauterine Device (IUD) & Contraceptives, Non-hormonal Medications, Others), By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), By End-user (Hospital Pharmacies, Retail Pharmacies, other) and Regional Analysis, 2023-2030 ... U.S. FDA approval for Myfembree (relugolix), a medication specifically indicated for ... MYFEMBREE, the first regular or Myfembree (relugolix) is an FDA-approved, once-daily ... a once-daily combination treatment of relugolix plus estradiol and norethindrone ... Endometriosis: Market Research Report This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period ... Pharmaceuticals for Women's Health: Global Markets Report Scope: While women’s health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on ... Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an ... Non Hormonal Contraceptives Market for Women’s Health by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030 The non hormonal contraceptives market is expected to reach USD 1.8 billion in 2021 and anticipated to grow at a CAGR of 22% during the forecast period 2021-2030. According to the World Health Organization (WHO), around one-third of clinical conditions ... Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major uterine fibroids markets are expected to exhibit a CAGR of 2.99% during 2024-2034. The uterine fibroids market has been comprehensively analyzed in IMARC's new report titled "Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, ... Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the race? Rising star Anti Androgens – Third generation ... Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 ... years. The launch of Myovant / Pfizer’s Relugolix combination tablet, ObsEva’s Yselty (linzagolix ... Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major dysmenorrhea markets reached a value of US$ 10.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.44% during 2024-2034. The dysmenorrhea market has been ... Global Prostate Cancer Treatment Market - 2025-2033 Overview The global prostate cancer treatment market size reached US$ 13.22 billion in 2024 and is expected to reach US$ 28.10 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033. Prostate cancer, a common type of cancer, ... India Prostate Cancer Market - 2025 -2033 India Prostate Cancer Treatment Market: Industry Outlook The India Prostate Cancer Treatment market reached US$ 12,146.00 Million in 2023, with a rise of US$ 13,220.00 Million in 2024 and is expected to reach US$ 28,097.00 Million by 2033, growing at a ... |